Roche’s Phase IIb Studie zu Prasinezumab verfehlt primären Endpunkt, deutet jedoch auf möglichen klinischen Nutzen bei Frühstadium der Parkinson-Krankheit hin.
These forward-looking statements are based on Prothena’s current expectations and beliefs and involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in the initiation and conduct of clinical trials, the availability of … Weiterlesen
